POM-V Prescription Required

CIDR 1.38 g Vaginal Delivery System for Cattle

Active ingredient: Progesterone

Form

Vaginal delivery system

Species

Cattle

Manufacturer

Zoetis UK Limited

VMD MA No.

42058/5114

What it's used for

For the control of the oestrous cycle in cycling cows and heifers, including: - insemination (FTAI) programmes. - To be used in combination with prostaglan...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Progesterone

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

CIDR 1.38 g Vaginal Delivery System for Cattle — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For the control of the oestrous cycle in cycling cows and heifers, including:
-
insemination (FTAI) programmes.
-
To be used in combination with prostaglandin F2 
Use as recommended, normally results in oestrus 48-96 hours after device removal
with the majority of animals showing oestrus within 48-72 hours.
For induction and synchronisation of oestrus in Fixed Time Artificial Insemination
(FTAI) protocols:
-
(PGF2α) or analogue.
-
Gonadotrophin releasing hormone (GnRH) or analogue and or
analogue.
- or analogue and
equine chorionic gonadotrophin (eCG).

Amended pages: January 2024
AN: 02654/2022

Do not use in cows or heifers, with abnormal or immature genital tracts, or with genital
infections.
Do not use in pregnant cattle.
Do not use within the first 35 days after calving.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.

Cattle (cows and heifers):
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
vaginal discharge
, vulva irritation /
vaginal irritation
1
observed at removal of insert, this discharge generally clears between the time of
removal and insemination and has not been seen to affect conception rates following
treatment.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

The progesterone treatment alone, according to dosage regimen proposed, is not
sufficient to induce oestrus and ovulation in all cycling females. Progesterone-based
breeding protocols are reproduction management tools and should not replace
adequate feeding and general health management. The choice of a specific protocol
should be based on the requirements of the individual herd and it is advisable to
examine cycling ovarian activity before using the progesterone treatment.
The response of cows and heifers to progesterone-based synchronisation protocols is
influenced by the physiological state at the time of treatment.
Responses to treatment can vary either across herds or across cows within herds.
However, the percentage of cows displaying oestrus within a given period is usually
greater than in untreated cows and the subsequent luteal phase is of normal duration.

Special precautions for use in animals
Animals in poor condition, whether from illness, inadequate nutrition, or other factors,
may respond poorly to treatment.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Progesterone is a potent steroid hormone and may cause adverse effects on the
reproductive system in cases of high or prolonged exposure. As adverse effects on
unborn children cannot be ruled out, pregnant women should avoid using this veterinary
medicinal product.
The veterinary medicinal product may cause skin and eye irritation as well as allergic
skin rashes.
Avoid accidental contact with the eyes. In case of accidental ocular exposure, flush the
eyes thoroughly with water.
Persons administering the veterinary medicinal product should avoid contact with the
silicone section; pregnant women should completely avoid handling the veterinary
medicinal product.
The device should be inserted using the veterinary medicinal product specific
applicator.
Personal protective equipment consisting of gloves should be worn when handling the
veterinary medicinal product during insertion and removal.
Ensure correct administration; including use of a non-irritant antiseptic and lubrication
(see section 4.9).
Wash hands and exposed skin with soap and water after use.

Amended pages: January 2024
AN: 02654/2022
Do not eat, drink or smoke while handling the veterinary medicinal product.
Special precautions for the protection of the environment:
Not applicable.

None known.

Do not store above 30 °C.

horizontally until some resistance is encountered.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.